Status:
RECRUITING
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Eligibility Criteria
Inclusion
- ≥18 years of age
- Physician-reported diagnosis of moderate to severe plaque psoriasis
- Be newly initiating deucravacitinib
- Do not object to participate
Exclusion
- Currently participating in or planning to participate in an interventional clinical trial
- Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial
Key Trial Info
Start Date :
January 29 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2028
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT06701513
Start Date
January 29 2025
End Date
April 30 2028
Last Update
April 11 2025
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 060
Amiens, France, 80054
2
Cabinet Médical Elisabeth Lion
Angers, France, 49100
3
Local Institution - 045
Argenteuil, France, 95107
4
CH ARRAS
Arras, France, 62000